Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib

	Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib
	Wang, Deping; Feng, Yubing; Zhuang, Xiaoxi; Zhang, Fengxiang; Liu, Jianqi; Leng, Fang; Lang, Xingfen; Bai, Yang; She, Miaoqin; Tu, Zhengchao
刊名	JOURNAL OF MEDICINAL CHEMISTRY
	2013
卷号	56 期号:3
ISSN号	0022-2623
学科主题	Pharmacology & Pharmacy
语种	英语
内容类型	期刊论文
源URL	[http://ir.foo.ac.cn/handle/2SETSVCV/274]
专题	中国科学院广州生物医药与健康研究院
推荐引用方式 GB/T 7714	Wang, Deping,Feng, Yubing,Zhuang, Xiaoxi,et al. Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib[J]. JOURNAL OF MEDICINAL CHEMISTRY,2013,56(3).
APA	Wang, Deping.,Feng, Yubing.,Zhuang, Xiaoxi.,Zhang, Fengxiang.,Liu, Jianqi.,...&Ren, Xiaomei.(2013).Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib.JOURNAL OF MEDICINAL CHEMISTRY,56(3).
MLA	Wang, Deping,et al."Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib".JOURNAL OF MEDICINAL CHEMISTRY 56.3(2013).